Top Markets
Coin of the day
TaiGen Biopharmaceuticals Holdings Limited TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

4157
Clasificación en acciones #18388
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Precio por acción
$0.28078542
Capitalización bursátil
$199.87M
Cambio (1 día)
-0.34%
Cambio (1 año)
-10.19%
País
TW
Comercio TaiGen Biopharmaceuticals Holdings Limited (4157)

Categoría

Ratio P/S de TaiGen Biopharmaceuticals Holdings Limited (4157)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de TaiGen Biopharmaceuticals Holdings Limited, el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de TaiGen Biopharmaceuticals Holdings Limited desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH